AGENUS INC
AGEN evidence brief
What we can confirm
- BioSniper Score:
- 4.2 / 10
- Market Cap:
- $448.5M
- Lead Asset:
- agen2373 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for AGEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AGEN
Agenus Inc. is a clinical-stage immuno-oncology company developing next-generation antibody combinations, primarily botensilimab (anti-CTLA-4) and balstilimab (anti-PD-1), with a lead program advancing into Phase 3 for MSS colorectal cancer.
Key risk: Limited cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$448.5M
Cash Runway
—
Lead Asset
agen2373 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 13 clinical trials for AGENUS INC.
Agenus Inc. is a clinical-stage immuno-oncology company developing next-generation antibody combinations, primarily botensilimab (anti-CTLA-4) and balstilimab (anti-PD-1), with a lead program advancing into Phase 3 for MSS colorectal cancer.
- Cash and equivalents were $18.7M as of 2026-06-30 [sec].
- Total revenue was $34.5M as of 2026-06-30 [sec].
- Shareholders' equity was -$199.1M as of 2026-06-30 [sec].
- Lead program botensilimab plus balstilimab (BOT+BAL) is advancing into Phase 3 for MSS colorectal cancer [news · published 2026-05-26].
- Botensilimab has received Fast Track regulatory status [pipeline].
What works
- Botensilimab is a next-generation, Fc-enhanced anti-CTLA-4 antibody designed to activate both innate and adaptive anti-tumor immune responses [pipeline].
- The BOT+BAL combination has advanced into Phase 3 development for MSS colorectal cancer, indicating clinical progress [news · published 2026-05-26].
- Agenus has generated translational data showing survival associated with systemic inflammation and tumor immune activity from its Phase 1b C-800-01 study [news · published 2026-02-20].
What to weigh
- Cash and equivalents were only $18.7M as of 2026-06-30, which may limit operational runway [sec].
- Shareholders' equity was negative at -$199.1M as of 2026-06-30, reflecting accumulated deficits [sec].
- The company faces a critical evaluation of clinical development progress relative to its cash position [news · published 2026-05-26].
From the filings
Quoted directly from source documents.
Catalyst timeline
- 2017-12-18 · Phase 2 start for AGEN1884 + AGEN2034 combination — Initiated a Phase 1/2 trial of AGEN1884 (anti-CTLA-4) in combination with AGEN2034 (anti-PD-1) in advanced solid tumors.
- 2019-03-20 · Phase 1 start for AGEN1181 (botensilimab) — Started a Phase 1 study of botensilimab as monotherapy and in combination with balstilimab in advanced cancer.
- 2019-06-01 · Phase 2 start for AGEN2034 combinations — Initiated a Phase 2 trial of balstilimab as monotherapy or in combination with AGEN1884 or placebo in women with certain cancers.
Risks & what to watch (3)›
Key risks
- Limited cash runway — Cash of $18.7M as of 2026-06-30 may constrain operations and development [sec].
- Negative equity
- Clinical execution risk — Phase 3 trial for MSS colorectal cancer requires significant resources and successful outcomes [news · published 2026-05-26].
What to watch
- Phase 3 development progress of BOT+BAL in MSS colorectal cancer [news · published 2026-05-26].
- Cash runway and any new financing or partnership announcements [news · published 2026-05-26].
- Regulatory updates on botensilimab's Fast Track status and potential approvals [pipeline].
- Further clinical data from ongoing Phase 2 studies in renal cell carcinoma, pancreatic cancer, and gastroesophageal cancer [pipeline][news · published 2026-04-18].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run AGENUS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AGENUS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
N/A
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
87
Total value held
$30.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,440,232 | $4.8M |
| vanguard portfolio management llc | 1,195,109 | $4.0M |
| siren, l.l.c. | 1,064,250 | $3.6M |
| marshall wace, llp | 688,203 | $2.3M |
| blackrock, inc. | 545,662 | $1.8M |
| geode capital management, llc | 348,395 | $1.2M |
| morgan stanley | 295,821 | $988K |
| renaissance technologies llc | 285,646 | $954K |
| man group plc | 278,980 | $932K |
| raymond james financial inc | 239,554 | $800K |
Showing top 10 of 87 institutional holders of AGENUS INC. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 11.2%
- Days to cover
- 8.5
- Shares short
- 4,284,092
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AGEN short interestGovernance
Frequently asked questions
What is the AI investment thesis for AGENUS INC?
Agenus Inc. is a clinical-stage immuno-oncology company developing next-generation antibody combinations, primarily botensilimab (anti-CTLA-4) and balstilimab (anti-PD-1), with a lead program advancing into Phase 3 for MSS colorectal cancer.
What is AGENUS INC's lead drug candidate?
AGENUS INC's most advanced tracked candidate is agen2373 (Phase 2) for advanced solid tumors.
Who is the CEO of AGENUS INC?
Dr. Garo H. Armen Ph.D. is the chief executive officer of AGENUS INC (AGEN).
Where is AGENUS INC headquartered?
AGENUS INC (AGEN) is headquartered in Lexington, MA, United States.
What therapeutic areas does AGENUS INC focus on?
AGENUS INC develops therapies across Oncology, Immunology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.